Corrigendum to “Telmisartan inhibits AGE-induced podocyte damage and detachment” [Microvascular Research 88 (2013) 79–83](S0026286213000666)(10.1016/j.mvr.2013.04.006);Telmisartan inhibits AGE-induced podocyte damage and detachment

Microvascular Research

Volumn 88, Issue , 2013, Pages 79-83

  Fukami, Kei ^a   Yamagishi, Sho ichi ^a   Kaifu, Kumiko ^a   Matsui, Takanori ^a   Kaida, Yusuke ^a   Ueda, Seiji ^a   Takeuchi, Masayoshi ^b   Asanuma, Katsuhiko ^c   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BOVINE SERUM ALBUMIN; LACTATE DEHYDROGENASE; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DETACHMENT; CELL FUNCTION; CONTROLLED STUDY; DNA DAMAGE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; ANIMAL; CELL ADHESION; CYTOLOGY; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOTTING, WESTERN; CELL ADHESION; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DNA DAMAGE; GLYCOSYLATION END PRODUCTS, ADVANCED; L-LACTATE DEHYDROGENASE; MICE; PODOCYTES;

EID: 84878572529     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2016.08.003     Document Type: Erratum

References (29)

1. Burlinson B. The in vitro and in vivo comet assays. Methods Mol. Biol. 2012, 817:143-163.
2. Chuang P.Y., Dai Y., Liu R., He H., Kretzler M., Jim B., Cohen C.D., He J.C. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011, 6:e23566.
3. Cravedi P., Ruggenenti P., Remuzzi G. Intensified inhibition of renin-angiotensin system: a way to improve renal protection?. Curr. Hypertens. Rep. 2005, 9:430-436.
4. Dobler D., Ahmed N., Song L., Eboigbodin K.E., Thornalley P.J. Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. Diabetes 2006, 55:1961-1969.
5. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M.E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004, 66:2137-2147.
6. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., Nishitani T., Gohda T., Ni Z., Qian J., Horikoshi S., Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 2006, 21:299-313.
7. Ishibashi Y., Matsui T., Ohta K., Tanoue R., Takeuchi M., Asanuma K., Fukami K., Okuda S., Nakamura K.I., Yamagishi S.I. PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc. Res. 2013, 85:54-58.
8. Kashiwagi M., Shinozaki M., Hirakata H., Tamaki K., Hirano T., Tokumoto M., Goto H., Okuda S., Fujishima M. Locally activated renin-angiotensin system associated with TGF-beta1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J. Am. Soc. Nephrol. 2000, 11:616-624.
9. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol. Res. 2010, 61:34-39.
10. Matsui T., Nishino Y., Maeda S., Takeuchi M., Yamagishi S. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc. Res. 2011, 81:269-273.
11. Müller-Krebs S., Kihm L.P., Madhusudhan T., Isermann B., Reiser J., Zeier M., Schwenger V. Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol. Dial. Transplant. 2012, 27:3129-3136.
12. Mundel P., Heid H.W., Mundel T.M., Krüger M., Reiser J., Kriz W. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J. Cell Biol. 1997, 139:193-204.
13. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem. Biophys. 2007, 48:147-157.
14. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
15. Shankland S.J. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006, 69:2131-2147.
16. Shi S., Yu L., Sun Y., Chen J., Khitrov G., Merkenschlarger M., Holzman L.B., Zhang W., Mundel P., Bottinger E.P. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 2008, 19:2159-2169.
17. Soldatos G., Cooper M.E. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res. Clin. Pract. 2008, 82:S75-S79.
18. Stieger N., Worthmann K., Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab. Res. Rev. 2011, 27:207-215.
19. Stitt A.W., Bucala R., Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann. N. Y. Acad. Sci. 1997, 811:115-127.
20. Stitt-Cavanagh E., MacLeod L., Kennedy C.R. The podocyte in diabetic kidney disease. Sci. World J. 2009, 9:1127-1139.
21. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 1999, 5:393-405.
22. White K.E. Research into the glomerular podocyte-is it relevant to diabetic nephropathy?. Diabet. Med. 2006, 23:715-719.
23. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
24. Yamagishi S., Matsui T. Nitric oxide, a Janus-faced therapeutic target for diabetic microangiopathy-friend or foe?. Pharmacol. Res. 2011, 64:187-194.
25. Yamagishi S., Takeuchi M., Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs Exp. Clin. Res. 2005, 31:45-51.
26. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:20213-20220.
27. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 2007, 8:952-959.
28. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
29. Zhou L.L., Cao W., Xie C., Tian J., Zhou Z., Zhou Q., Zhu P., Li A., Liu Y., Miyata T., Hou F.F., Nie J. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 2012, 82:759-770.